Our study presents some limitations, as the relatively small number of the different immunohistochemically defined subtypes of breast carcinoma; the evaluation of more patients with hormone receptor expression, HER2 positive and triple negative would allow the analysis of the clinical impact of PD-L1 expression and sTIL counts within each group. This evidence concerns the gene ERBB2 and breast carcinoma.